Free shipping over €250 · Tracked, discreet delivery in Europe
UU library
Every peptide, mapped to the body.
160 compounds, from approved medicines to early research molecules. Each one filed by the system research looks at, with its regulatory status and the strength of the evidence behind it.
- Compounds
- 160
- Research summaries
- 39
- At UU
- 56
- Approved medicine71
Approved as a medicine by the FDA or the EMA for at least one indication. Approval covers the named indication and formulation only.
- In clinical trials19
In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.
- Research compound53
Not approved as a medicine by the FDA or the EMA. Some are registered in individual countries. Supplied for laboratory research only.
- Cosmetic ingredient17
Used as a topical cosmetic ingredient. Cosmetic use is not a medicinal approval, and most evidence comes from manufacturer and small panel studies.
Reviewed October 2026
In the UU catalog
Researched, batch-tested, ready to ship.
Compounds UU carries that have a full research summary in the library.
27 compounds · Immune & airways
Immune & airways27
Thymic peptides, antimicrobial peptides and complement inhibitors studied in immune research.
- ResearchAt UU
Thymosin alpha-1
Thymalfasin · Zadaxin
Thymic peptide
A 28-residue thymic peptide registered in a number of countries but not by the FDA or the EMA. Studied as an immune modulator in sepsis and viral infection.
Human trialsShop - ResearchAt UU
Bronchogen
Short bioregulator peptide
A bioregulator peptide associated with bronchial tissue in Russian research. Published evidence is limited.
Summary pendingShop - Approved
Bacitracin
Polypeptide antibiotic
A polypeptide antibiotic best known in topical ointments for minor skin wounds.
Summary pending - In trials
Brilacidin
Defensin mimetic
A synthetic small molecule modelled on host defence peptides. Studied in trials for oral mucositis and infection.
Summary pending - Approved
Colistin
Polymyxin E
Polymyxin antibiotic
A cyclic peptide antibiotic kept as a last-line option for multidrug-resistant Gram-negative infections.
Summary pending - Approved
Cyclosporine
Ciclosporin
Calcineurin inhibitor
A cyclic peptide from a soil fungus. Approved to suppress transplant rejection and for some autoimmune conditions.
Summary pending - Approved
Dalbavancin
Dalvance · Xydalba
Lipoglycopeptide antibiotic
A long-acting lipoglycopeptide antibiotic approved for skin and soft tissue infections.
Summary pending - Approved
Daptomycin
Cubicin
Lipopeptide antibiotic
A cyclic lipopeptide antibiotic approved for serious Gram-positive infections.
Summary pending - Approved
Ecallantide
Kalbitor
Plasma kallikrein inhibitor
A small recombinant protein approved by the FDA for acute attacks of hereditary angioedema.
Summary pending - Approved
Enfuvirtide
Fuzeon
HIV fusion inhibitor
A 36-residue peptide that blocks HIV from fusing with cells. Approved for HIV-1 infection.
Summary pending - Approved
Glatiramer acetate
Copaxone
Random amino acid copolymer
A mixture of polypeptides built from four amino acids. Approved for relapsing forms of multiple sclerosis.
Summary pending - Approved
Icatibant
Firazyr
Bradykinin B2 antagonist
A synthetic decapeptide approved for acute attacks of hereditary angioedema.
Summary pending - In trials
LTX-315
Oncopore
Oncolytic peptide
A peptide derived from lactoferricin that disrupts tumour cell membranes. Studied in early cancer immunotherapy trials.
Summary pending - Approved
Motixafortide
Aphexda
CXCR4 antagonist
A cyclic peptide that blocks CXCR4. Approved to mobilise stem cells for collection before transplant in multiple myeloma.
Summary pending - In trials
Nangibotide
TREM-1 inhibitor
A 12-residue peptide that blocks the TREM-1 inflammatory receptor. Studied in clinical trials in septic shock.
Summary pending - Approved
Pegcetacoplan
Empaveli · Aspaveli
Complement C3 inhibitor
A pegylated cyclic peptide that blocks complement C3. Approved for paroxysmal nocturnal haemoglobinuria and geographic atrophy.
Summary pending - Research
Thymulin
Zinc-dependent thymic hormone
A zinc-binding nonapeptide made by the thymus. Studied in animal models of inflammation and pain.
Summary pending - Approved
Vancomycin
Glycopeptide antibiotic
A glycopeptide antibiotic in use since the 1950s, approved for serious Gram-positive infections.
Summary pending - Approved
Zilucoplan
Zilbrysq
Complement C5 inhibitor
A macrocyclic peptide that blocks complement C5. Approved for generalised myasthenia gravis.
Summary pending
The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.